Skip to main content
Top
Gepubliceerd in: Tijdschrift voor Urologie 2-3/2016

26-02-2016 | Artikel

Validatie van een nieuwe urinetest voor klinisch significante prostaatkanker

Auteurs: drs. Rianne J. Hendriks, drs. Siebren Dijkstra, dr. Erik B. Cornel, Sander A. Jannink, Hans de Jong, dr. Daphne Hessels, Frank P. Smit, dr. Willem J.G. Melchers, dr. Gisèle Leyten, prof. dr. Theo M. de Reijke, dr. Henk Vergunst, dr. Paul Kil, drs. Ben C. Knipscheer, dr. Christina A. Hulsbergen-van de Kaa, prof. dr. Peter F.A. Mulders, dr. Inge M. van Oort, prof. dr. Jack A. Schalken

Gepubliceerd in: Tijdschrift voor Urologie | Uitgave 2-3/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Om overdiagnostiek en overbehandeling te verminderen, is er dringend behoefte aan een test voor detectie van klinisch significant prostaatcarcinoom. In deze studie werd een model ontwikkeld (met behulp van geïdentificeerde biomarkers HOXC6, DLX1, TDRD1 en HOXC4) voor het voorspellen van hooggradig prostaatcarcinoom in prostaatbiopten. In twee prospectieve, multicenterstudies (cohort A: n = 492; cohort B: n = 371) werd urine verzameld voorafgaand aan prostaatbiopten. De resultaten van cohort A werden gebruikt voor het model en gevalideerd in het onafhankelijke cohort B. De HOXC6-DLX1-score had de hoogste area under the curve (0,76; 95 %-betrouwbaarheidsinterval (BI) = 0,71–0,81), met een specificiteit van 36 % bij een sensitiviteit van 92 %. De score was gecorreleerd met de Gleason-score van de prostaatbiopten; subgroepanalyse bevestigde de potentiële meerwaarde van deze urinetest voor patiënten met lage PSA-waarden (< 10 ng/ml).
De conclusie is dat de HOXC6-DLX1-score het risico op hooggradig prostaatcarcinoom in prostaatbiopten voorspelt. Het gebruik van deze urinetest kan het aantal onnodige biopten reduceren, vooral bij patiënten met een lage PSA-waarde.
Literatuur
1.
go back to reference Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374–83.CrossRefPubMedPubMedCentral Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374–83.CrossRefPubMedPubMedCentral
2.
go back to reference Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 2009;101(19):1325–9.CrossRefPubMedPubMedCentral Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 2009;101(19):1325–9.CrossRefPubMedPubMedCentral
3.
go back to reference Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095–101.CrossRefPubMed Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095–101.CrossRefPubMed
4.
go back to reference Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clini Chem. 2006;52(6):1089–95.CrossRef Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clini Chem. 2006;52(6):1089–95.CrossRef
5.
go back to reference Gittelman MC, Hertzman B, Bailen J, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013;190(1):64–9.CrossRefPubMed Gittelman MC, Hertzman B, Bailen J, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013;190(1):64–9.CrossRefPubMed
6.
go back to reference Bussemakers MJ, Bokhoven A van, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23):5975–9.PubMed Bussemakers MJ, Bokhoven A van, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23):5975–9.PubMed
7.
go back to reference Hessels D, Klein Gunnewiek JM, Oort I van, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44(1):8–15. discussion -6.CrossRefPubMed Hessels D, Klein Gunnewiek JM, Oort I van, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44(1):8–15. discussion -6.CrossRefPubMed
8.
go back to reference Auprich M, Chun FK, Ward JF, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol. 2011;59(1):96–105.CrossRefPubMed Auprich M, Chun FK, Ward JF, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol. 2011;59(1):96–105.CrossRefPubMed
9.
go back to reference Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69(3):532–5.CrossRefPubMed Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69(3):532–5.CrossRefPubMed
10.
go back to reference Ploussard G, Haese A, Van Poppel H, et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int. 2010;106(8):1143–7.CrossRefPubMed Ploussard G, Haese A, Van Poppel H, et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int. 2010;106(8):1143–7.CrossRefPubMed
11.
go back to reference Leyten GH, Hessels D, Smit FP, et al. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res. 2015;21(13):3061–70.CrossRefPubMed Leyten GH, Hessels D, Smit FP, et al. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res. 2015;21(13):3061–70.CrossRefPubMed
12.
go back to reference Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3(6):1101–8.CrossRefPubMed Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3(6):1101–8.CrossRefPubMed
13.
go back to reference Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008;68(3):645–9.CrossRefPubMedPubMedCentral Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008;68(3):645–9.CrossRefPubMedPubMedCentral
14.
go back to reference Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014;65(3):534–42.CrossRefPubMed Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014;65(3):534–42.CrossRefPubMed
15.
go back to reference Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011;3(94):94ra72.PubMedPubMedCentral Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011;3(94):94ra72.PubMedPubMedCentral
16.
go back to reference Poppel H van, Haese A, Graefen M, et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int. 2012;109(3):360–6.CrossRefPubMed Poppel H van, Haese A, Graefen M, et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int. 2012;109(3):360–6.CrossRefPubMed
17.
go back to reference Vugt HA van, Kranse R, Steyerberg EW, et al. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. Eur J Cancer. 2012;48(12):1809–15.CrossRefPubMed Vugt HA van, Kranse R, Steyerberg EW, et al. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. Eur J Cancer. 2012;48(12):1809–15.CrossRefPubMed
18.
go back to reference Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4,0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.CrossRefPubMed Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4,0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.CrossRefPubMed
19.
go back to reference Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529–34.CrossRefPubMed Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529–34.CrossRefPubMed
20.
go back to reference Wolters T, Kwast TH van der, Vissers CJ, et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol. 2010;34(1):35–43.CrossRefPubMed Wolters T, Kwast TH van der, Vissers CJ, et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol. 2010;34(1):35–43.CrossRefPubMed
21.
go back to reference Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167(6):2435–9.CrossRefPubMed Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167(6):2435–9.CrossRefPubMed
22.
go back to reference Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261(1):46–66.CrossRefPubMed Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261(1):46–66.CrossRefPubMed
23.
go back to reference Baco E, Rud E, Eri LM, et al. A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy. Eur Urol. 2015. Baco E, Rud E, Eri LM, et al. A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy. Eur Urol. 2015.
24.
go back to reference Tonttila PP, Lantto J, Paakko E, et al. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. Eur Urol. 2015. Tonttila PP, Lantto J, Paakko E, et al. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. Eur Urol. 2015.
25.
go back to reference Budaus L, Leyh-Bannurah SR, Salomon G, et al. Initial Experience of Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol. 2015. Budaus L, Leyh-Bannurah SR, Salomon G, et al. Initial Experience of Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol. 2015.
Metagegevens
Titel
Validatie van een nieuwe urinetest voor klinisch significante prostaatkanker
Auteurs
drs. Rianne J. Hendriks
drs. Siebren Dijkstra
dr. Erik B. Cornel
Sander A. Jannink
Hans de Jong
dr. Daphne Hessels
Frank P. Smit
dr. Willem J.G. Melchers
dr. Gisèle Leyten
prof. dr. Theo M. de Reijke
dr. Henk Vergunst
dr. Paul Kil
drs. Ben C. Knipscheer
dr. Christina A. Hulsbergen-van de Kaa
prof. dr. Peter F.A. Mulders
dr. Inge M. van Oort
prof. dr. Jack A. Schalken
Publicatiedatum
26-02-2016
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Urologie / Uitgave 2-3/2016
Print ISSN: 2211-3037
Elektronisch ISSN: 2211-4718
DOI
https://doi.org/10.1007/s13629-015-0113-0